Steven D. Averbuch, MD

Steven Averbuch

Vice President,Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb

Dr. Averbuch is currently Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb Company based in Lawrenceville, NJ, USA. In this role, Steve serves as the Executive Sponsor of the Translational R&D teams across the Full Development and Life Cycle Management pipeline. Steve also leads the Pharmacodiagnostics Center of Excellence with its mission to drive biomarker strategy, optimize biomarker knowledge and tools across all of R&D and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to BMS products.Steve joined BMS in 2006. Previously he co-led the Oncology early strategy team and he was the executive sponsor for Oncology Transition Teams for the execution of Phase 2 Oncology programs. He has made significant Global Clinical Research contributions to business development and he has participated in seven successful acquisitions.

Steve previously held positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.

Dr. Averbuch has authored over 60 peer reviewed publications and book chapters and he is a co-author on one patent. He is currently on the Personalized Medicine Coalition Board of Directors, the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation and he is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations.